NO20055128L - Kompleks av ras-farnesyltransferase inhibitor, en cyklodekstrin og etanol - Google Patents

Kompleks av ras-farnesyltransferase inhibitor, en cyklodekstrin og etanol

Info

Publication number
NO20055128L
NO20055128L NO20055128A NO20055128A NO20055128L NO 20055128 L NO20055128 L NO 20055128L NO 20055128 A NO20055128 A NO 20055128A NO 20055128 A NO20055128 A NO 20055128A NO 20055128 L NO20055128 L NO 20055128L
Authority
NO
Norway
Prior art keywords
ras
ethanol
complex
cyclodextrin
farnesyltransferase inhibitor
Prior art date
Application number
NO20055128A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055128D0 (no
Inventor
Anne Marie Smith
Michael Cucolo
Munir N Nassar
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20055128D0 publication Critical patent/NO20055128D0/no
Publication of NO20055128L publication Critical patent/NO20055128L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20055128A 2003-05-02 2005-11-02 Kompleks av ras-farnesyltransferase inhibitor, en cyklodekstrin og etanol NO20055128L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46728703P 2003-05-02 2003-05-02
PCT/US2004/013114 WO2004098501A2 (en) 2003-05-02 2004-04-27 Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol

Publications (2)

Publication Number Publication Date
NO20055128D0 NO20055128D0 (no) 2005-11-02
NO20055128L true NO20055128L (no) 2005-12-01

Family

ID=33435047

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055128A NO20055128L (no) 2003-05-02 2005-11-02 Kompleks av ras-farnesyltransferase inhibitor, en cyklodekstrin og etanol

Country Status (6)

Country Link
US (1) US7157446B2 (enExample)
EP (1) EP1622628A4 (enExample)
JP (2) JP2006525341A (enExample)
IS (1) IS8102A (enExample)
NO (1) NO20055128L (enExample)
WO (1) WO2004098501A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210145816A1 (en) * 2019-11-15 2021-05-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
HU199444B (en) * 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
YU45837B (sh) * 1988-01-18 1992-07-20 LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d. Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1251615B (it) * 1991-10-04 1995-05-17 Golgi Sa Medicamento ad attivita' antielastasica.
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
US5646131A (en) 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
CZ20012601A3 (cs) * 1999-01-21 2002-05-15 Bristol-Myers Squibb Company Komplex inhibitoru ras-farnesyltranferasy a sulfobutylether-7beta-cyklodextrinu nebo 2-hydroxypropyl-beta-cyklodextrinu a způsob

Also Published As

Publication number Publication date
EP1622628A4 (en) 2010-03-03
WO2004098501A3 (en) 2005-03-17
US7157446B2 (en) 2007-01-02
NO20055128D0 (no) 2005-11-02
JP2012072161A (ja) 2012-04-12
US20040235790A1 (en) 2004-11-25
EP1622628A2 (en) 2006-02-08
IS8102A (is) 2005-10-28
WO2004098501A2 (en) 2004-11-18
JP2006525341A (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
CR6682A (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorios, autoinmunes y respiratorias
NO20052497D0 (no) Fremgangsmater for selektiv inhibering av Janus tyrosinkinase 3 (JAK3).
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
DK1569899T3 (da) Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
NO20083114L (no) Polysykliske indazolderivater som er ERK-inhibitorer
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
NO2012006I2 (no) Telaprevir og enhver terapeutisk ekvivalent form derav som er beskyttet av basispatentet, slik som farmasøytisk akseptable salter og/eller solvater av telaprevir eller solvater av slike salter
WO2004094388A3 (en) Indazole derivatives as jnk inhibitors
CY1112499T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
MXPA05010174A (es) Derivados de indol e indolina sustituidos.
ATE323695T1 (de) Benzimidazolderivative und ihre verwendung als prodrugs für protonenpumpenhemmer
NO20080036L (no) Raskt opploselig farmasoytisk sammensetning for inhibering av ovulasjon
ATE279933T1 (de) Arzneimittel zur hemmung des nf-kb transkriptionsfaktors
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
TR200403436T2 (tr) Kristalin 1-metilkarbapenem türevleri.
MXPA05009282A (es) Derivados de anilina sustituidos.
ATE308540T1 (de) Antithrombosemittel
NO20055128L (no) Kompleks av ras-farnesyltransferase inhibitor, en cyklodekstrin og etanol
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200501900A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application